Zepbound, approved in 2023, is a breakthrough medication designed for chronic weight management in obese or overweight adults with at least one weight-related condition, such as high cholesterol, high blood pressure, or type 2 diabetes. It should be used alongside a low-calorie diet and increased physical activity.
Obesity and overweight are major health concerns linked to some of the leading causes of death, including heart disease, stroke, and diabetes. This groundbreaking drug is making waves and is raking in millions in sales, but it’s important to note that just like any medication, it has common and serious side effects.
Understanding these side effects and how to manage them is key to ensuring a safe and effective treatment experience. This article explores Zepbound’s side effects and offers practical management tips to help users navigate their treatment journey confidently.
Common Zepbound Side Effects
The following are the typical side effects reported with Zepbound:
1. Gastrointestinal (GI) Side Effects
The most common side effects of Zepbound are primarily GI-related. Most were mild to moderate in severity, with only a few instances leading to treatment discontinuation. These include:
-
- Nausea
- Diarrhea
- Constipation
- Dyspepsia
- Vomiting
- Abdominal pain
- Burping
- Gastroesophageal reflux disease
Here are some tips to manage GI side effects:
-
- Eat easily digestible foods like crackers, toast, or bananas.
- Opt for smaller, more frequent portions as large meals can worsen nausea.
- Sip on clear fluids such as water, ginger ale, or herbal teas like ginger or peppermint.
- Avoid greasy or spicy foods because they irritate the stomach and worsen symptoms.
- Avoid lying down immediately after meals. Sit upright to aid digestion.
- Minimize exposure to foods or environments with strong odors, which can trigger nausea.
- Drink water, electrolyte solutions, or broths to prevent dehydration.
- Stick to the BRAT diet: bananas, rice, applesauce, and toast, which are gentle on the stomach.
- Avoid high-fiber, greasy, spicy, or dairy-based foods that may irritate the digestive system.
- Consult your healthcare provider for anti-diarrheal or anti-constipation medicines, especially if the symptoms persist or you have blood in your stool.
- Give your body time to recover by resting and avoiding intense physical activity.
2. Injection site reactions
Zepbound is administered via subcutaneous injection, and users may experience injection site reactions such as swelling, itchiness, or redness. In the clinical trial, site reactions were reported by 18 participants at the 5 mg dose, 36 participants at 10 mg, and 29 participants at 15 mg.
Applying a cold or warm compress for 10–20 minutes can help alleviate these symptoms. However, if the reactions persist, it’s advisable to consult a healthcare provider for treatment options or to discuss whether to stop or continue the medication.
A Zepbound user opened up on Reddit about persistent injection site reactions, describing redness and swelling that felt like a bad mosquito bite. Despite trying remedies like icing, warming the injection, and antihistamines, the issue persisted.
3. Fatigue
In a 72-week study involving 287 patients, fatigue was reported by 3 participants in the 5 mg dose group, 5 participants in the 10 mg group, and 6 participants in the 15 mg group. Fatigue, a common side effect of Zepbound, is often described as a general feeling of tiredness or low energy. Fortunately, this symptom typically improves as the body adapts to the treatment. In the meantime, maintaining a healthy diet, staying hydrated, and prioritizing rest can help manage it effectively.
4. Hypersensitivity Reactions
Hypersensitivity reactions may occur with Zepbound. Immediate hypersensitivity reactions (occurring within one day of administration) were reported in 2.1% of Zepbound-treated patients compared to 0.4% of placebo patients. Non-immediate reactions occurred in 3.5% of Zepbound users.
Most of these hypersensitivity reactions were skin-related, such as rash or itching. If symptoms are observed, discontinuing the medication and seeking immediate medical care is vital to ensure safety and prevent complications.
5. Hair Loss
Research shows that hair loss was observed in 5.1% of patients on the 5 mg dose of Zepbound, 4.9% on the 10 mg dose, and 5.7% on the 15 mg dose. However, it’s often temporary and improves over time. Using mild hair care products and limiting heat styling can help.
Serious Side Effects of Zepbound
While less common, Zepbound may cause serious side effects, including:
1. Risk of Thyroid C-cell Tumors
Zepbound has been associated with thyroid cancer in animal studies, though it is uncertain whether this risk extends to humans. Thyroid cancer can be life-threatening if not identified and treated promptly. Patients should contact their doctor immediately if they experience symptoms such as a neck lump, difficulty breathing or swallowing, or persistent hoarseness.
2. Severe Gastrointestinal Adverse Reactions
Severe gastrointestinal effects, including persistent vomiting and severe abdominal pain, were reported in a clinical trial. Eleven patients at the 5 mg dose, 20 patients at the 10 mg dose, and 21 patients at the 15 mg dose experienced adverse gastrointestinal symptoms.
These symptoms can disrupt the gastrointestinal system and may lead to complications such as dehydration. To manage these effects, patients are advised to stay hydrated and avoid foods that trigger symptoms. If symptoms persist or worsen, seeking medical attention is essential.
3. Acute Kidney Injury
Acute kidney injury may occur due to dehydration from severe vomiting or diarrhea. A study linked tirzepatide use to increased kidney monitoring needs. Patients should stay hydrated and monitor urinary output. Immediate medical attention is necessary if kidney function declines.
4. Acute Gallbladder Disease
Zepbound may increase the risk of gallbladder issues, including gallstones or cholecystitis. Symptoms include severe upper abdominal pain, nausea, or fever. A low-fat diet and maintaining a healthy weight can reduce gallbladder issues.
5. Acute Pancreatitis

One out of each dosage group had acute pancreatitis in the 72-week study. Acute pancreatitis is a rare but serious side effect. The symptoms are severe upper abdominal pain radiating to the back, nausea, and vomiting.
6. Serious Hypersensitivity Reactions
Postmarketing reports have documented serious hypersensitivity reactions, such as swelling and breathing problems. Severe hypersensitivity reactions occurred in 0.1% of Zepbound-treated patients, with no cases reported in the placebo group in clinical trials.
Patients should be advised to discontinue Zepbound and seek immediate medical attention if hypersensitivity reactions occur. The medication is contraindicated in individuals with a history of serious hypersensitivity to tirzepatide or its excipients.
7. Hypoglycemia
In a Zepbound study, 1.4 to 1.6% of patients experienced hypoglycemia. The drug may cause hypoglycemia, especially when combined with other glucose-lowering medications. Symptoms include dizziness, sweating, and confusion. Carry a quick source of sugar, like candies or glucose tablets, and monitor blood sugar levels regularly.
8. Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus
Rapid blood sugar changes can worsen diabetic retinopathy in patients with type 2 diabetes. Regular eye exams and careful blood sugar control are key. Report any vision changes, such as blurriness or floaters, to a doctor promptly.
9. Suicidal Behavior and Ideation
Reports of suicidal ideation have been noted with GLP-1 receptor agonists, including 5 cases involving Zepbound. The rapid weight loss may impact emotional and psychological well-being. Close monitoring is recommended, particularly for patients with a history of mental health conditions, and further research is needed to understand these effects better.
10. Pulmonary Aspiration During General Anesthesia or Deep Sedation
Zepbound delays gastric emptying, which may increase the risk of pulmonary aspiration during surgeries or procedures requiring general anesthesia or deep sedation. Rare postmarketing reports have noted aspiration despite adherence to fasting guidelines. There is insufficient data to determine whether adjusting fasting recommendations or pausing Zepbound before surgery can reduce this risk.
Related Articles
Takeaway
Zepbound is a game-changer for weight management, but being informed about common and serious side effects is essential. Common Zepbound side effects like nausea or diarrhea are manageable with interventions like hydration and diet adjustments.
Keep an eye out for rare but serious risks such as hypersensitivity reactions or gallbladder problems because quick action can make all the difference. From hair loss to suicidal thoughts, knowing what to expect helps you stay one step ahead. Partnering with a healthcare provider is essential to ensure a safe and effective Zepbound treatment journey.
Frequently Asked Questions
Sources
Eli Lilly and Company. (n.d.). Zepbound prescribing information. Retrieved from https://pi.lilly.com/us/zepbound-uspi.pdf
National Center for Biotechnology Information. (n.d.). PMC10614464. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10614464/
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Acid reflux (GER and GERD) in adults. Retrieved from https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd-adults
U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Guirguis, A., Chiappini, S., Papanti P, G. D., Vickers-Smith, R., Harris, D., Corkery, J. M., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 82, 82–91. https://doi.org/10.1016/j.euroneuro.2024.02.003
U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Eli Lilly and Company. (n.d.). Zepbound medication information. Retrieved from https://zepbound.lilly.com/
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., Fretes, J. O., Coronel, M. J., Gutnisky, L. L., Frechtel, G. D., Gelersztein, E., Aizenberg, D., Maldonado, N., . . . Nardandrea, J. P. (2023). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA, 331(1), 38. https://doi.org/10.1001/jama.2023.24945
Memorial Sloan Kettering Cancer Center. (n.d.). Tirzepatide patient education. Retrieved from https://www.mskcc.org/cancer-care/patient-education/medications/adult/tirzepatide
Guirguis, A., Chiappini, S., P, G. P., Vickers-Smith, R., Harris, D., Corkery, J., Arillotta, D., Floresta, G., Martinotti, G., & Schifano, F. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European Neuropsychopharmacology, 82, 82–91. https://doi.org/10.1016/j.euroneuro.2024.02.003




